Ipilimumab receives Priority Review

FDA accepted for filing and granted Priority Review to a BLA from Bristol-Myers Squibb Co. (NYSE:BMY) for ipilimumab to treat metastatic melanoma in pre-treated patients. The PDUFA date is Dec. 25. Th...